Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate UpdateGlobeNewsWire • 04/26/23
Tiziana Life Sciences Ltd. Regains Compliance with Nasdaq Listing Minimum Bid Price RuleGlobeNewsWire • 04/24/23
Tiziana Life Sciences to File Alzheimer's IND for Intranasal Foralumab in Q2 2023GlobeNewsWire • 04/20/23
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple SclerosisAccesswire • 04/19/23
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 DiabetesGlobeNewsWire • 04/18/23
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ:TLSA) First-in-Class Foralumab Is Showing PromiseAccesswire • 04/17/23
Tiziana Life Sciences plans to investigate intranasal foralumab for the treatment of Long COVIDProactive Investors • 04/13/23
Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVIDGlobeNewsWire • 04/13/23
Tiziana Life Sciences says intranasal foralumab presented at ‘Preserving the Brain' scientific conference and exhibit in ShanghaiProactive Investors • 04/10/23
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in ShanghaiGlobeNewsWire • 04/10/23
Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology ConferenceGlobeNewsWire • 04/04/23
Tiziana Life Sciences reports positive data on intranasal anti-CD3 mAb in intracerebral hemorrhageProactive Investors • 04/04/23
Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral HemorrhageGlobeNewsWire • 04/04/23
Tiziana Life Sciences says anti-CD3 mAb research for treatment of Alzheimer's disease to be presented at international conferenceProactive Investors • 03/31/23
Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer's Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders Conference in SweGlobeNewsWire • 03/31/23
Tiziana Life Sciences plans to accept US FDA recommendations and start Phase 2 study in Q3 2023Proactive Investors • 03/28/23
Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)GlobeNewsWire • 03/28/23
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEOGlobeNewsWire • 03/22/23
Tiziana Life Sciences receives positive coverage on foralumab in Forbes articleProactive Investors • 03/17/23
Tiziana Life Sciences hails publication in science journal of article on mechanism of action for intranasal foralumabProactive Investors • 03/08/23
Tiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal ForalumabGlobeNewsWire • 03/08/23
Tiziana Life Sciences says IND filed for Phase 2 study of milciclib in combination with gemcitabine for non-small cell lung cancerProactive Investors • 01/04/23
Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung CancerGlobeNewsWire • 01/04/23